Your browser doesn't support javascript.
loading
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato, Laura; de Tribolet-Hardy, Jonas; Lee, Irene; Rottenberg, Jaice T; Coleman, Ilsa; Melchers, Diana; Houtman, René; Xiao, Tengfei; Li, Wei; Uo, Takuma; Sun, Shihua; Kuznik, Nane C; Göppert, Bettina; Ozgun, Fatma; van Royen, Martin E; Houtsmuller, Adriaan B; Vadhi, Raga; Rao, Prakash K; Li, Lewyn; Balk, Steven P; Den, Robert B; Trock, Bruce J; Karnes, R Jeffrey; Jenkins, Robert B; Klein, Eric A; Davicioni, Elai; Gruhl, Friederike J; Long, Henry W; Liu, X Shirley; Cato, Andrew C B; Lack, Nathan A; Nelson, Peter S; Plymate, Stephen R; Groner, Anna C; Brown, Myles.
Afiliação
  • Cato L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • de Tribolet-Hardy J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland.
  • Lee I; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Rottenberg JT; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Coleman I; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Melchers D; PamGene International B.V., 5211 HH Den Bosch, the Netherlands.
  • Houtman R; PamGene International B.V., 5211 HH Den Bosch, the Netherlands.
  • Xiao T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harva
  • Li W; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, MA 02215, USA.
  • Uo T; Department of Medicine, University of Washington School of Medicine and GRECC-VAPSHCS, Seattle, WA 98104, USA.
  • Sun S; Department of Medicine, University of Washington School of Medicine and GRECC-VAPSHCS, Seattle, WA 98104, USA.
  • Kuznik NC; Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany.
  • Göppert B; Institute of Microstructure Technology, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany.
  • Ozgun F; School of Medicine, Koç University, 34450 Istanbul, Turkey.
  • van Royen ME; Department of Pathology, Erasmus Optical Imaging Centre, Erasmus MC, 3015 GE Rotterdam, the Netherlands.
  • Houtsmuller AB; Department of Pathology, Erasmus Optical Imaging Centre, Erasmus MC, 3015 GE Rotterdam, the Netherlands.
  • Vadhi R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Rao PK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Li L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Balk SP; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
  • Den RB; Department of Radiation Oncology, Sidney Kimmel Cancer Center, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Trock BJ; Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
  • Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
  • Jenkins RB; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Klein EA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Davicioni E; GenomeDx Inc., San Diego, CA 92121, USA.
  • Gruhl FJ; Institute of Microstructure Technology, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany.
  • Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Liu XS; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, MA 02215, USA.
  • Cato ACB; Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany.
  • Lack NA; School of Medicine, Koç University, 34450 Istanbul, Turkey; Vancouver Prostate Center, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
  • Nelson PS; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
  • Plymate SR; Department of Medicine, University of Washington School of Medicine and GRECC-VAPSHCS, Seattle, WA 98104, USA. Electronic address: splymate@u.washington.edu.
  • Groner AC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland. Electr
  • Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: myles_brown@dfci.harvard.edu.
Cancer Cell ; 35(3): 401-413.e6, 2019 03 18.
Article em En | MEDLINE | ID: mdl-30773341
ABSTRACT
Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increased expression of full-length AR (ARfl) or expression of dominantly active splice variants such as ARv7. We show in ARv7-dependent CRPC models that ARv7 binds together with ARfl to repress transcription of a set of growth-suppressive genes. Expression of the ARv7-repressed targets and ARv7 protein expression are negatively correlated and predicts for outcome in PCa patients. Our results provide insights into the role of ARv7 in CRPC and define a set of potential biomarkers for tumors dependent on ARv7.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Androgênicos / Processamento Alternativo / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: Cancer Cell Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Androgênicos / Processamento Alternativo / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: Cancer Cell Ano de publicação: 2019 Tipo de documento: Article